REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Community-acquired Pneumonia, Influenza, COVID-19
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
-
University of Florida, Jacksonville, Florida, United States, 32209
Augusta University, Augusta, Georgia, United States, 30912
University of Illinois Health, Chicago, Illinois, United States, 60612
Tulane Medical Center, New Orleans, Louisiana, United States, 70112
University of Michigan, Ann Arbor, Michigan, United States, 48109
Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States, 27157-1009
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States, 43210
Oregon Health and Science University, Portland, Oregon, United States, 97239-3098
University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States,
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
UMC Utrecht,
Steve Webb, Prof, STUDY_CHAIR, Monash University, Study Chair REMAP-CAP Australia
Colin McArthur, Dr, STUDY_CHAIR, Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
Marc Bonten, Prof, STUDY_CHAIR, UMC Utrecht, Study Chair REMAP-CAP Europe
Lennie Derde, MD, STUDY_CHAIR, UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
John Marshall, Prof, STUDY_CHAIR, Unity Health Toronto, Study Chair REMAP-CAP Canada
Derek Angus, Prof, STUDY_CHAIR, University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA
2028-02